OR WAIT null SECS
(Frenova Rapid STart Up) to Speed Clinical Trial Initiation
Exclusive Alliance With Physician Investigators Reduces Administrative Delays and Elevates Value Offered to Pharma and Medical Device Sponsors
(Waltham, Mass; Feb. 11, 2016) - Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, announced today the launch of F1RST Up (Frenova Rapid STart Up), an exclusive alliance with recognized leading physician investigators in the nephrology research community.
F1RST Up accelerates study startup by eliminating the administrative and contracting burdens often cited as primary reasons clinical trials are delayed.
Frenova, a Fresenius Medical Care North America (FMCNA) company, has a 16-year history dedicated exclusively to improving the lives of patients living with kidney disease. F1RST Up represents an exclusive group of clinical research sites carefully selected from Frenova’s investigative site network of more than 200 physician investigators who provide care to approximately 600,000 kidney disease patients.
F1RST Up is comprised of large, high-performing research site businesses with demonstrated clinical research success in vascular access and care, cardio-renal conditions, chronic kidney disease (CKD), end stage renal disease (ESRD), cardiovascular disease, rare diseases, infectious diseases and transplant.
“F1RST Up was conceived and organized with value for all of our stakeholders in mind,” said Kurt Mussina, general manager of Frenova. “We worked very closely with our F1RST Up physician partners and clients to both identify and magnify the value drivers for our sites, sponsors and patients. F1RST Up works because it takes a no-nonsense approach to moving immediately from study award to study start, and that is the foremost value driver for sponsors.”